NADH in the Prevention and Treatment of Parkinson’s Disease: Mechanisms and Research Progress

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra, leading to motor and cognitive dysfunction. Recent studies have highlighted the potential of Nicotinamide Adenine Dinucleotide (NADH) in the prevention and treatment of PD. This paper aims to summarize the current understanding of the pathogenesis of PD, the mechanism of NADH in treating PD, and the results of research conducted by various universities and institutions on NADH’s potential for treating or preventing the disease. NADH demonstrates its therapeutic potential through various mechanisms, including enhancing ATP production, exhibiting antioxidant properties, and modulating neurotransmitter systems. While preliminary results from clinical trials are encouraging, further research is needed to establish the optimal dosing, safety, and long-term efficacy of NADH in PD patients. This review emphasizes the need for large-scale, randomized, double-blind, placebo-controlled trials to confirm NADH’s therapeutic potential in